Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLDB | US
-0.04
-0.60%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
6.58
6.82
6.95
6.53
Solid Biosciences Inc. a life science company engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003 a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT a gene therapy program for the treatment of Friedreich's ataxia; AVB-401 a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies including dual gene expression a technology for packaging multiple transgenes into one vector as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
20.1%1 month
59.6%3 months
91.9%6 months
82.9%-
-
1.41
0.13
0.11
-3.69
1.16
-
-97.67M
253.96M
253.96M
-
-
-
-100.00
-50.81
6.83
8.90
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.50
Range1M
2.23
Range3M
4.60
Rel. volume
0.87
Price X volume
1.18M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ESSA Pharma Inc | EPIX | Drug Manufacturers-Specialty & Generic | 6.04 | 267.99M | -0.33% | n/a | 0.27% |
Alpha Teknova Inc. Common Stock | TKNO | Drug Manufacturers-Specialty & Generic | 4.92 | 262.25M | 2.71% | n/a | 39.24% |
Procaps Group S.A. Ordinary Shares | PROC | Drug Manufacturers-Specialty & Generic | 2.1612 | 243.84M | -3.52% | 4.37 | 0.00% |
Galectin Therapeutics Inc | GALT | Drug Manufacturers-Specialty & Generic | 2.82 | 175.62M | 3.68% | n/a | -113.78% |
LFCR | LFCR | Drug Manufacturers-Specialty & Generic | 5.38 | 166.05M | 8.25% | 19.80 | 241.85% |
Zomedica Pharmaceuticals Corp | ZOM | Drug Manufacturers-Specialty & Generic | 0.138 | 137.72M | 5.83% | n/a | 1.10% |
CRDL | CRDL | Drug Manufacturers-Specialty & Generic | 1.97 | 137.67M | 2.07% | n/a | 1.07% |
Aceto Corporation | ACET | Drug Manufacturers-Specialty & Generic | 1.42 | 117.01M | -4.70% | n/a | 8.14% |
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.7699 | 112.70M | 2.15% | n/a | 36.36% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.8874 | 110.64M | 0.40% | n/a | -148.05% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Unifi Inc | UFI | Textile Manufacturing | 6.74 | 123.04M | -2.46% | n/a | 52.56% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Culp Inc | CULP | Textile Manufacturing | 5.95 | 74.32M | -2.30% | n/a | 11.29% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.33 | 5.20M | 0.03% | n/a | 0.97% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.69 | 17.21 | Cheaper |
Ent. to Revenue | 1.16 | 334.38 | Cheaper |
PE Ratio | - | 26.92 | - |
Price to Book | 1.41 | 12.15 | Cheaper |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 91.86 | 68.34 | Riskier |
Debt to Equity | 0.13 | -1.00 | Expensive |
Debt to Assets | 0.11 | 0.48 | Cheaper |
Market Cap | 253.96M | 5.31B | Emerging |